Drug Baron https://validator.w3.org/feed/docs/rss2.html A quite revolution in the world of proteomics Front-Page Lessons from Monte Carlo Models: Why Drug Development is Hard Claims that AI will “revolutionise pharma R&D” are (almost entirely) hype An Open Letter To FDA Regarding Eteplirse The Hidden Superpower of Strategic Focus Cellular social networks give cancer cells a cloak of invincibility Re-Imagining Med Chem Strategies: the Tyranny of the n+1 Compound The Cambridge Partnership Why Small Beats Big: the Hidden Cost of Too Many Voices The history – and the future – of antibody discovery technologies Why Sarepta’s most recent failure in DMD was entirely predictable One dose or two? What the debate about COVID vaccination teaches us about science – and its limitations Even scale-up chemistry is not “just cooking” #Unshackled: The evolving definition of asset-centricity Forget about greed, President Trump: the villain responsible for high drug prices is inefficiency How to find a drug: the past, present and future of small molecule drug discovery Blog COVID19: Serology is harder than it looks The Cult Of DNA-centricity Why Too Many Clinical Trials Fail — And A Simple Solution That Could Increase Returns On Pharma R&D The Lone Biotech Bear? Beta-Amyloid: The Emperor Really Does Have No Clothes A DrugBaron Glossary Is This The Future Of Late-Stage Drug Development? Constructing better multivariate biomarker composites The HDL myth: how misuse of biomarker data cost Roche and its investors $5billion Environmental Pollutants: Opening a Soup-Can of Worms The interleukin lottery: playing the odds on numbers 9 and 16 Smoke Screen: The intensifying debate about population screening generates more heat than light Personalized Medicine Demands Investment in Innovative Diagnostics: Will the Returns be High Enough? Ultra-sensitive NMR-based diagnosis for infectious diseases: the tortoise races the hare again Chemokines as biomarkers for cancer: Time to revisit an old friend? Finding exogenous biomarkers of heart disease: humans are ecosystems too! Biomarkers: lessons from history The final frontier – post-genomic biomarkers Biomarkers: A Band-Aid for Bioscience FDA guidance on the use of biomarkers as drug development tools Biomarkers: standing the test of time means good initial study design Anti-PCSK9 Drugs: An Ingenious Solution For A Problem That’s Mostly Already Solved Portola’s APEX Trial Design Was Too Clever By Half Viagra, Melanoma And The Problem With Big Data New Data On Alzheimer’s Drug Candidates Changes Nothing Is The Superiority Of Entresto Just An Illusion? DMD Drugs: An Existential Threat To The FDA? How Does Meldonium, The Drug Maria Sharapova Took, Work? Cult of Crystallography Spotting Baby Unicorns The (Statistical) Power and the Glory Why clinical CROs hate eCRF systems – and why you should love them